Medicenna Therapeutics Corp. (MDNAF)
| Market Cap | 26.42M -57.1% |
| Revenue (ttm) | n/a |
| Net Income | -13.07M |
| EPS | -0.16 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 138 |
| Open | 0.2745 |
| Previous Close | 0.3018 |
| Day's Range | 0.2745 - 0.2913 |
| 52-Week Range | 0.2290 - 1.4300 |
| Beta | 1.96 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 13, 2026 |
About Medicenna Therapeutics
Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkin... [Read more]
News
Medicenna Announces Oral Presentation of New Bizaxofusp Results in Recurrent Glioblastoma at the 2026 Society for Neuro-Oncology Annual Meeting
TORONTO and HOUSTON, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superki...
Medicenna Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference
Multiple clinical and regulatory milestones are expected in the next three to six months, including top-line data for MDNA11 and new data for bizaxofusp, both targeting significant unmet needs in oncology. The pipeline also includes first-in-class bifunctional and conditionally activated Superkines, with strong partnering and market potential.
Medicenna Therapeutics Slides: Corporate presentation
Medicenna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on September 16, 2026.
Medicenna Therapeutics Reports First Quarter Fiscal 2027 Financial Results and Announces Oral Presentations at Upcoming Conferences
Updated MDNA11 clinical results from ABILITY-1 will be presented during an oral session at an upcoming medical conference
Medicenna Therapeutics Registration statement: Q1 2027
Medicenna Therapeutics filed a registration statement on August 13, 2026, providing details about a securities offering with the SEC.
Medicenna Therapeutics Registration statement: Q1 2027
Medicenna Therapeutics filed a registration statement on August 13, 2026, providing details about a securities offering with the SEC.
Medicenna Therapeutics Earnings release: Q1 2027
Medicenna Therapeutics released its Q1 2027 earnings on August 13, 2026, summarizing the period's financial results.
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer a...
Medicenna Therapeutics Registration statement: Q4 2026
Medicenna Therapeutics filed a registration statement on June 25, 2026, providing details about a securities offering with the SEC.
Medicenna Therapeutics Registration statement: Q4 2026
Medicenna Therapeutics filed a registration statement on June 25, 2026, providing details about a securities offering with the SEC.
Medicenna Strengthens U.S. Patent Estate with Newly Issued and Allowed Patents Across its IL-2, IL-4 and IL-13 Superkine Platforms
TORONTO, June 11, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superkines for targe...
Medicenna's MDNA11 Potential in Earlier Line Melanoma Setting Highlighted in Presentation of the NEO-CYT trial at ASCO 2026
NEO-CYT positions MDNA11 in a frontline neoadjuvant melanoma setting, where immunotherapy before surgery may help generate deeper and more durable anti-tumor immune responses Up to 80 patients with l...
Medicenna Therapeutics Transcript: Lytham Partners Spring 2026 Investor Conference
The conference highlighted a robust pipeline of engineered cytokine therapies targeting cancer and autoimmune diseases, with late-stage assets showing strong efficacy and safety. Multiple clinical and regulatory milestones are expected by 2027, supported by ongoing financing.
Medicenna Announces Closing of Public Offering of Units Raising CDN$4.44 Million to Support Lead Programs
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES
Medicenna Announces the Filing of its Prospectus Supplement and Investment Term Sheet
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 22, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the ”Compa...
Medicenna Announces the Launch of a Marketed Public Offering of Securities
NOT FOR DISSEMINATION INTO THE UNITED STATES OR FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES TORONTO and HOUSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Compa...
Medicenna and Fondazione Melanoma Onlus Announce First Patient Dosed in the NEO-CYT Study of MDNA11 in Neoadjuvant Melanoma
NEO-CYT marks the first evaluation of MDNA11 in earlier-stage cancers, as a potentially curative treatment; extends development beyond the heavily pretreated metastatic setting of the ongoing Phase 1/...
Medicenna and Fondazione Melanoma Onlus Announce Presentation on NEOCYT Trial at ASCO 2026
TORONTO and HOUSTON, April 30, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company developing Superki...
Medicenna Therapeutics Transcript: 2026 Bloom Burton & Co. Healthcare Investor Conference
MDNA11 is showing strong response rates in solid tumors, with pivotal trial planning underway. MDNA113, a novel bispecific anti-PD-1, demonstrated superior safety and efficacy in preclinical models and is set for clinical entry by year-end. MDNA55 is advancing toward phase III with a partner.
Medicenna Therapeutics presents new preclinical data from MDNA113
Medicenna Therapeutics (MDNAF) presented new positive preclinical data from MDNA113, its first-in-class tumor-anchored and conditionally activated anti-PD-1 x IL-2 bifunctional Superkine, at the Ameri...
Medicenna to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
TORONTO and HOUSTON, April 14, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the dev...
Medicenna to Present Preclinical Data from its First-in-Class Tumor Anchored and Conditionally Activated Anti-PD-1-IL-2 Bifunctional Superkine at the AACR Annual Meeting 2026
MDNA113 is a novel IL-13Rα2 tumor-targeted and “masked” anti-PD-1-IL-2 Superkine (anti-PD1-IL-2 SK), engineered to precisely deliver clinically validated anti-PD1 and IL-2 SK to the tumor microenviro...
Medicenna Therapeutics Slides: Corporate presentation
Medicenna Therapeutics has posted slides in relation to its latest quarterly earnings report, which was published on March 13, 2026.
Medicenna Therapeutics Announces Participation in Upcoming Conferences
TORONTO and HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQX: MDNAF), a clinical-stage immunotherapy company focused on the deve...
Medicenna Therapeutics reports Q3 EPS (5c) vs. (7c) last year
“We delivered strong clinical results in 2025 with our ABILITY-1 trial and 2026 is shaping up to be a milestone-rich year across our pipeline,” said Dr Fahar Merchant, President and…